A Randomised Effectiveness-implementation Trial for Evaluating Dietary and Manual Treatment With Osteopathic Techniques on Quality of Life and on Modulation of the Inflammatory State of Patients Diagnosed With Breast Cancer Undergoing Antiestrogenic Hormonal Treatment.
Breast cancer patients under hormonal therapy may experience significant adverse events related to this treatment and as a result, failure to adhere to adjuvant therapies or discontinuation of treatment has been reported to be high. Promoting weight control and the adoption of healthy lifestyle habits in breast cancer survivors has an impact on hormonal status, quality of life and physical functioning, contributing to reduce cancer recurrence risk, cancer-related and chronic-condition-related mortality. Manipulation procedures, such as manual treatment with osteopathic techniques, have positive effects on osteoarticular pain, peripheral neuropathies, anxious-depressive disorders, asthenia and sleep disorders, also improving immune and neuroendocrine responses. The aim of this study is to evaluate the effects of dietary intervention and manual treatment with osteopathic techniques in women diagnosed with breast cancer under antiestrogenic hormonal treatment through the assessment of: * modifications of quality of life (QoL) * frequency and severity of symptoms related to antiestrogenic hormonal treatment * body weight * body composition * food habits * metabolic and inflammatory state * physical performance * patient's satisfaction to multidisciplinary treatment. This study focuses on patient's centricity evaluating the effects that long lasting adjuvant therapies have on breast cancer survivors. Improving personalized patient's treatment through collaborative interactions between clinicians, osteopaths and nutrition specialists might result in implementation strategies to determine novel evidence-based treatments for ameliorating patient's adherence to oncological therapies, impacting prognosis and survival.
• Age \>18 years
• Voluntary written informed consent
• Histologically confirmed estrogen receptor-positive invasive breast cancer or in situ breast cancer after breast surgery
• Absence of locoregional relapse or distant metastasis
• Premenopausal or postmenopausal status
• Hormonal therapy with tamoxifen and/or LHRH analogues or aromatase inhibitors
• Patients with or without neoadjuvant or adjuvant chemotherapy
• Patients with a BMI \> 18.5 kg/m\^2
• Absence of language barrier